Invasive serogroup B meningococci in England following three years of 4CMenB vaccination - First real-world data
Copyright © 2021. Published by Elsevier Ltd..
OBJECTIVES: In 2015 the UK became the first country to implement the meningococcal B (MenB) vaccine, 4CMenB, into the national infant program. 4CMenB is expected to cover meningococci expressing sufficient levels of cross-reactive proteins. This study presents clonal complex, 4CMenB antigen genotyping, and 4CMenB coverage data for all English invasive MenB isolates from 2014/15 (1 year pre-vaccine) through 2017/18 and compares data from vaccinated and unvaccinated ≤3 year olds.
METHODS: Vaccine coverage of all invasive MenB isolates from 2014/15 to 2017/18 (n = 784) was analysed using the Meningococcal Antigen Typing System. Genotyping utilised the Meningococcus Genome Library.
RESULTS: Among ≤3 year olds, proportionally fewer cases in vaccinees (1, 2 or 3 doses) were associated with well-covered strains e.g. cc41/44 (20.5% versus 36.4%; P<0.01) and antigens e.g. PorA P1.4 (7.2% versus 17.3%; P = 0.02) or fHbp variant 1 peptides (44.6% vs 69.1%; P<0.01). Conversely, proportionally more cases in vaccinees were associated with poorly-covered strains e.g. cc213 (22.9% versus 9.6%; P<0.01) and antigens e.g. variant 2 or 3 fHbp peptides (54.2% versus 30.9%; P<0.01).
CONCLUSIONS: 4CMenB reduces disease due to strains with cross-reactive antigen variants. No increase in absolute numbers of cases due to poorly covered strains was observed in the study period.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:84 |
|---|---|
| Enthalten in: |
The Journal of infection - 84(2022), 2 vom: 01. Feb., Seite 136-144 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lucidarme, Jay [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4CMenB |
|---|
| Anmerkungen: |
Date Completed 07.04.2022 Date Revised 07.04.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jinf.2021.11.015 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM333759214 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM333759214 | ||
| 003 | DE-627 | ||
| 005 | 20231225222317.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jinf.2021.11.015 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1112.xml |
| 035 | |a (DE-627)NLM333759214 | ||
| 035 | |a (NLM)34838814 | ||
| 035 | |a (PII)S0163-4453(21)00579-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lucidarme, Jay |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Invasive serogroup B meningococci in England following three years of 4CMenB vaccination - First real-world data |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.04.2022 | ||
| 500 | |a Date Revised 07.04.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021. Published by Elsevier Ltd. | ||
| 520 | |a OBJECTIVES: In 2015 the UK became the first country to implement the meningococcal B (MenB) vaccine, 4CMenB, into the national infant program. 4CMenB is expected to cover meningococci expressing sufficient levels of cross-reactive proteins. This study presents clonal complex, 4CMenB antigen genotyping, and 4CMenB coverage data for all English invasive MenB isolates from 2014/15 (1 year pre-vaccine) through 2017/18 and compares data from vaccinated and unvaccinated ≤3 year olds | ||
| 520 | |a METHODS: Vaccine coverage of all invasive MenB isolates from 2014/15 to 2017/18 (n = 784) was analysed using the Meningococcal Antigen Typing System. Genotyping utilised the Meningococcus Genome Library | ||
| 520 | |a RESULTS: Among ≤3 year olds, proportionally fewer cases in vaccinees (1, 2 or 3 doses) were associated with well-covered strains e.g. cc41/44 (20.5% versus 36.4%; P<0.01) and antigens e.g. PorA P1.4 (7.2% versus 17.3%; P = 0.02) or fHbp variant 1 peptides (44.6% vs 69.1%; P<0.01). Conversely, proportionally more cases in vaccinees were associated with poorly-covered strains e.g. cc213 (22.9% versus 9.6%; P<0.01) and antigens e.g. variant 2 or 3 fHbp peptides (54.2% versus 30.9%; P<0.01) | ||
| 520 | |a CONCLUSIONS: 4CMenB reduces disease due to strains with cross-reactive antigen variants. No increase in absolute numbers of cases due to poorly covered strains was observed in the study period | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a 4CMenB | |
| 650 | 4 | |a England | |
| 650 | 4 | |a MATS | |
| 650 | 4 | |a Meningococcal antigen typing system | |
| 650 | 4 | |a Meningococcal disease | |
| 650 | 4 | |a Serogroup B | |
| 650 | 4 | |a Vaccine coverage | |
| 650 | 7 | |a Antigens, Bacterial |2 NLM | |
| 650 | 7 | |a Meningococcal Vaccines |2 NLM | |
| 700 | 1 | |a Bai, Xilian |e verfasserin |4 aut | |
| 700 | 1 | |a Lekshmi, Aiswarya |e verfasserin |4 aut | |
| 700 | 1 | |a Clark, Stephen A |e verfasserin |4 aut | |
| 700 | 1 | |a Willerton, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Ribeiro, Sonia |e verfasserin |4 aut | |
| 700 | 1 | |a Campbell, Helen |e verfasserin |4 aut | |
| 700 | 1 | |a Serino, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a De Paola, Rosita |e verfasserin |4 aut | |
| 700 | 1 | |a Holland, Ann |e verfasserin |4 aut | |
| 700 | 1 | |a Louth, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a Ramsay, Mary E |e verfasserin |4 aut | |
| 700 | 1 | |a Ladhani, Shamez N |e verfasserin |4 aut | |
| 700 | 1 | |a Borrow, Ray |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of infection |d 1982 |g 84(2022), 2 vom: 01. Feb., Seite 136-144 |w (DE-627)NLM012791822 |x 1532-2742 |7 nnns |
| 773 | 1 | 8 | |g volume:84 |g year:2022 |g number:2 |g day:01 |g month:02 |g pages:136-144 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jinf.2021.11.015 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 84 |j 2022 |e 2 |b 01 |c 02 |h 136-144 | ||